Engineering nanoparticles to locally activate T cells in the tumor microenvironment

A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy

(2018) Yu Mi et al.   ADVANCED MATERIALS

PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy

(2018) Xudong Zhang et al.   ADVANCED MATERIALS

Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy

(2018) Kuangda Lu et al.   Nature Biomedical Engineering

Engineering PD-1-Presenting Platelets for Cancer Immunotherapy

(2018) Xudong Zhang et al.   NANO LETTERS

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

(2018) Qian Chen et al.   Nature Nanotechnology

Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy

(2018) Quanyin Hu et al.   Nature Biomedical Engineering

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

(2017) Pedro N Aguiar et al.   Immunotherapy

Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma

(2017) Juliana Cano-Mejia et al.   Nanomedicine-Nanotechnology Biology and Medicine

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

(2017) Tyrel T. Smith et al.   Nature Nanotechnology

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy

(2017) Hengfeng Yuan et al.   Nature Nanotechnology

A STING-activating nanovaccine for cancer immunotherapy

(2017) Min Luo et al.   Nature Nanotechnology

Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy

(2017) Guizhi Zhu et al.   Nature Communications

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors

(2016) Yanqi Ye et al.   ACS Nano

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Photodynamic-therapy Activates Immune Response by disrupting Immunity Homeostasis of Tumor Cells, which Generates Vaccine for Cancer Therapy

(2016) Yuanhong Zheng et al.   International Journal of Biological Sciences

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

(2016) Kei Muro et al.   LANCET ONCOLOGY

Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy

(2016) Dangge Wang et al.   NANO LETTERS

Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody

(2016) Chao Wang et al.   NANO LETTERS

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

(2016) Kelly D Moynihan et al.   NATURE MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

(2016) Chunbai He et al.   Nature Communications

Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy

(2016) Qian Chen et al.   Nature Communications

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer

(2015) Sima Rahimian et al.   BIOMATERIALS

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy

(2015) Samuel G. Awuah et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthesis and bioactivity of a conjugate composed of green tea catechins and hyaluronic acid

(2015) Fan Lee et al.   Polymer Chemistry

Smart Human Serum Albumin-Indocyanine Green Nanoparticles Generated by Programmed Assembly for Dual-Modal Imaging-Guided Cancer Synergistic Phototherapy

(2014) Zonghai Sheng et al.   ACS Nano

Metal ions and solvents ratio co-regulate four new magnetic coordination polymers based upon an unsymmetric tricarboxylate acid ligand

(2014) Yuan-Pu Li et al.   DALTON TRANSACTIONS

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity

(2010) Abhishek D. Garg et al.   APOPTOSIS

Quantitative Imaging of Lymphatic Function with Liposomal Indocyanine Green

(2010) S. T. Proulx et al.   CANCER RESEARCH

Local Release of Highly Loaded Antibodies from Functionalized Nanoporous Support for Cancer Immunotherapy

(2010) Chenghong Lei et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors

(2009) Guopei Luo et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS